Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor

Journal of Medicinal Chemistry

Volumn 53, Issue 19, 2010, Pages 7048-7060

  Zhang, Yanan ^a   Gilliam, Anne ^a   Maitra, Rangan ^a   Damaj, M Imad ^b   Tajuba, Julianne M ^a   Seltzman, Herbert H ^a   Thomas, Brian F ^a  

^a RTI INTERNATIONAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 BROMOUNDECANENITRILE; 11,11' (BENZYLIMINO)DIUNDECANENITRILE; 5,5' (BENZYLIMINO)DIPENTANENITRILE; 5,5' (METHYLIMINO)DIPENTANENITRILE; 7,7' (BENZYLIMINO)DIHEPTANENITRILE; 9 BROMONONANENITRILE; 9,9' (BENZYLIMINO)DINONANENITRILE; CANNABINOID 1 RECEPTOR AGONIST; N(11 AMINOUNDECYL)UNDECANE 1,11 DIAMINE; N(5 AMINOPENTYL)PENTANE 1,5 DIAMINE; N(7 AMINOHEPTYL)HEPTANE 1,7 DIAMINE; N(9 AMINONONYL)NONANE 1,9 DIAMINE; N,N'(IMINODIETHANE 2,1 DIYL)BIS[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE]; N,N'(IMINODIHEPTANE 7,1 DIYL)BIS[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE]; N,N'(IMINODINONANE 9,1 DIYL)BIS[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE]; N,N'(IMINODIPENTANE 5,1 DIYL)BIS[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE]; N,N'(IMINODIPROPANE 3,1 DIYL)BIS[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE]; N,N'(IMINODIUNDECANE 11,1 DIYL)BIS[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE]; N[11 [(11 AMINOUNDECYL)(METHYL)AMINO]UNDECYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[11 [(11 AMINOUNDECYL)AMINO]UNDECYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[2 [(2 AMINOETHYL)AMINO]ETHYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[3 [(3 AMINOPROPYL)AMINO]PROPYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[5 [(5 AMINOPENTYL)AMINO]PENTYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[7 [(7 AMINOHEPTYL)(METHYL)AMINO]HEPTYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[7 [(7 AMINOHEPTYL)AMINO]HEPTYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[9 [(9 AMINONONYL)AMINO]NONYL] 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; N[[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOL 3 YL]CARBONYL]GLYCINE; N[[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOL 3 YL]CARBONYL]GLYCYL N (2 AMINOETHYL)GLYCINAMIDE; N[[5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOL 3 YL]CARBONYL]GLYCYLGLYCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; ANALGESIC AGENT; CALCIUM; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOHEXANOL DERIVATIVE; LIGAND; N,N'-(IMINODIHEPTANE-7,1-DIYL)BIS(5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-1H-PYRAZOLE-3-CARBOXAMIDE); N-(3-((3-AMINOPROPYL)AMINO)PROPYL)-5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYL-1H-PYRAZOLE-3-CARBOXAMIDE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EVALUATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; TAIL FLICK TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL LINE; CHEMISTRY; CRICETULUS; HAMSTER; HUMAN; IN VITRO STUDY; INVERSE AGONISM; METABOLISM; PROTEIN MULTIMERIZATION; RADIOASSAY; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANALGESICS; ANIMALS; BINDING SITES; BRAIN; CALCIUM; CELL LINE; CRICETINAE; CRICETULUS; CYCLOHEXANOLS; DRUG INVERSE AGONISM; HUMANS; IN VITRO TECHNIQUES; LIGANDS; MALE; MICE; PROTEIN MULTIMERIZATION; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957908601     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1006676     Document Type: Article

References (55)

1. De Petrocellis, L.; Cascio, M. G.; Di Marzo, V. The endocannabinoid system: a general view and latest additions Br. J. Pharmacol. 2004, 141 (5) 765-774
2. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 2006, 58 (3) 389-462
3. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 2002, 54 (2) 161-202
4. Mackie, K. Cannabinoid receptor homo- and heterodimerization Life Sci. 2005, 77 (14) 1667-1673
5. Wager-Miller, J.; Westenbroek, R.; Mackie, K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example Chem. Phys. Lipids 2002, 121 (1-2) 83-89
6. George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug Discovery 2002, 1 (10) 808-820
7. Lee, S. P.; O'Dowd, B. F.; Ng, G. Y.; Varghese, G.; Akil, H.; Mansour, A.; Nguyen, T.; George, S. R. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell Mol. Pharmacol. 2000, 58 (1) 120-128
8. Franco, R.; Casado, V.; Cortes, A.; Mallol, J.; Ciruela, F.; Ferre, S.; Lluis, C.; Canela, E. I. G-protein-coupled receptor heteromers: function and ligand pharmacology Br. J. Pharmacol. 2008, 153 (Suppl. 1) S90-98
9. Rios, C. D.; Jordan, B. A.; Gomes, I.; Devi, L. A. G-protein-coupled receptor dimerization: modulation of receptor function Pharmacol. Ther. 2001, 92 (2-3) 71-87
10. Minneman, K. P. Heterodimerization and surface localization of G protein coupled receptors Biochem. Pharmacol. 2007, 73 (8) 1043-1050
11. Milligan, G. G protein-coupled receptor dimerization: function and ligand pharmacology Mol. Pharmacol. 2004, 66 (1) 1-7
12. Milligan, G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery Drug Discovery Today 2006, 11 (11-12) 541-549
13. Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P. Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (52) 19208-19213
14. Portoghese, P. S. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 2001, 44 (14) 2259-2269
15. Messer, W. S., Jr. Bivalent ligands for G protein-coupled receptors Curr. Pharm. Des. 2004, 10 (17) 2015-2020
16. Peng, X.; Neumeyer, J. L. Kappa receptor bivalent ligands Curr. Top. Med. Chem. 2007, 7 (4) 363-373
17. Zheng, W.; Lei, L.; Lalchandani, S.; Sun, G.; Feller, D. R.; Miller, D. D. Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors Bioorg. Med. Chem. Lett. 2000, 10 (7) 627-630
18. Lalchandani, S. G.; Lei, L.; Zheng, W.; Suni, M. M.; Moore, B. M.; Liggett, S. B.; Miller, D. D.; Feller, D. R. Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype J. Pharmacol. Exp. Ther. 2002, 303 (3) 979-984
19. Tamiz, A. P.; Bandyopadhyay, B. C.; Zhang, J.; Flippen-Anderson, J. L.; Zhang, M.; Wang, C. Z.; Johnson, K. M.; Tella, S.; Kozikowski, A. P. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors J. Med. Chem. 2001, 44 (10) 1615-1622
20. Russo, O.; Berthouze, M.; Giner, M.; Soulier, J. L.; Rivail, L.; Sicsic, S.; Lezoualc'h, F.; Jockers, R.; Berque-Bestel, I. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers J. Med. Chem. 2007, 50 (18) 4482-4492
21. Meltzer, P. C.; Kryatova, O.; Pham-Huu, D. P.; Donovan, P.; Janowsky, A. The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8- heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters Bioorg. Med. Chem. 2008, 16 (4) 1832-1841
22. Christopoulos, A.; Grant, M. K.; Ayoubzadeh, N.; Kim, O. N.; Sauerberg, P.; Jeppesen, L.; El-Fakahany, E. E. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists J. Pharmacol. Exp. Ther. 2001, 298 (3) 1260-1268
23. Rajeswaran, W. G.; Cao, Y.; Huang, X. P.; Wroblewski, M. E.; Colclough, T.; Lee, S.; Liu, F.; Nagy, P. I.; Ellis, J.; Levine, B. A.; Nocka, K. H.; Messer, W. S., Jr. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists J. Med. Chem. 2001, 44 (26) 4563-4576
24. Beardsley, P. M.; Thomas, B. F. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders Behav. Pharmacol. 2005, 16 (5-6) 275-296
25. Bifulco, M.; Grimaldi, C.; Gazzerro, P.; Pisanti, S.; Santoro, A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects Mol. Pharmacol. 2007, 71 (6) 1445-1456
26. Francisco, M. E.; Seltzman, H. H.; Gilliam, A. F.; Mitchell, R. A.; Rider, S. L.; Pertwee, R. G.; Stevenson, L. A.; Thomas, B. F. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N -(piperidinyl)- 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1 H -pyrazole-3-carboxami de (SR141716) J. Med. Chem. 2002, 45 (13) 2708-2719
27. Thomas, B. F.; Francisco, M. E.; Seltzman, H. H.; Thomas, J. B.; Fix, S. E.; Schulz, A. K.; Gilliam, A. F.; Pertwee, R. G.; Stevenson, L. A. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N -(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 H -pyra zole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities Bioorg. Med. Chem. 2005, 13 (18) 5463-5474
28. Dyck, B.; Goodfellow, V. S.; Phillips, T.; Grey, J.; Haddach, M.; Rowbottom, M.; Naeve, G. S.; Brown, B.; Saunders, J. Potent imidazole and triazole CB1 receptor antagonists related to SR141716 Bioorg. Med. Chem. Lett. 2004, 14 (5) 1151-1154
29. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor Science 2000, 289 (5480) 739-745
30. Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors J. Med. Chem. 1986, 29 (10) 1855-1861
31. Neumeyer, J. L.; Zhang, A.; Xiong, W.; Gu, X. H.; Hilbert, J. E.; Knapp, B. I.; Negus, S. S.; Mello, N. K.; Bidlack, J. M. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors J. Med. Chem. 2003, 46 (24) 5162-5170
32. Peng, X.; Knapp, B. I.; Bidlack, J. M.; Neumeyer, J. L. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors J. Med. Chem. 2006, 49 (1) 256-262
33. Soriano, A.; Ventura, R.; Molero, A.; Hoen, R.; Casado, V.; Cortes, A.; Fanelli, F.; Albericio, F.; Lluis, C.; Franco, R.; Royo, M. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers J. Med. Chem. 2009, 52 (18) 5590-5602
34. Bonger, K. M.; van den Berg, R. J.; Heitman, L. H.; AP, I. J.; Oosterom, J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Synthesis and evaluation of homo-bivalent GnRHR ligands Bioorg. Med. Chem. 2007, 15 (14) 4841-4856
35. Wiley, J. L.; Jefferson, R. G.; Grier, M. C.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation J. Pharmacol. Exp. Ther. 2001, 296 (3) 1013-1022
36. Zhang, Y.; Burgess, J. P.; Brackeen, M.; Gilliam, A.; Mascarella, S. W.; Page, K.; Seltzman, H. H.; Thomas, B. F. Conformationally constrained analogues of N -(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1 H -pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations J. Med. Chem. 2008, 51 (12) 3526-3539
37. Seltzman, H. H.; Carroll, F. I.; Burgess, J. P.; Wyrick, C. D.; Burch, D. F. Tritiation of SR141716 by metallation-iodination-reduction: tritium-proton nOe study J. Labelled Compd. Radiopharm. 2002, 45 (1) 59-70
38. Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K. M.; McDonald, E.; Workman, P.; Drysdale, M. J. A fluorescence polarization assay for inhibitors of Hsp90 Anal. Biochem. 2006, 350 (2) 202-213
39. Wiley, J. L.; Wang, P.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Pyrazole Cannabinoids with Non-CB1, Non-CB2 Activity. Presented at the 19th Annual Symposium of the International Cannabinoid Research Society, St. Charles, IL, July 8-11, 2009.
40. Daniels, D. J.; Kulkarni, A.; Xie, Z.; Bhushan, R. G.; Portoghese, P. S. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes J. Med. Chem. 2005, 48 (6) 1713-1716
41. Xie, Z.; Bhushan, R. G.; Daniels, D. J.; Portoghese, P. S. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells Mol. Pharmacol. 2005, 68 (4) 1079-1086
42. Portoghese, P. S.; Edward, E. The role of concepts in structure-activity relationship studies of opioid ligands J. Med. Chem. 1992, 35 (11) 1927-1937 (Smissman-Bristol-Myers Squibb Award Address)
43. Neumeyer, J. L.; Peng, X.; Knapp, B. I.; Bidlack, J. M.; Lazarus, L. H.; Salvadori, S.; Trapella, C.; Balboni, G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores J. Med. Chem. 2006, 49 (18) 5640-5643
44. Bhushan, R. G.; Sharma, S. K.; Xie, Z.; Daniels, D. J.; Portoghese, P. S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 2004, 47 (12) 2969-2972
45. Bonger, K. M.; van den Berg, R. J.; Knijnenburg, A. D.; Heitman, L. H.; Ijzerman, A. P.; Oosterom, J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core Bioorg. Med. Chem. 2008, 16 (7) 3744-3758
46. Fulton, B. S.; Knapp, B. L.; Bidlack, J. M.; Neumeyer, J. L. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors Bioorg. Med. Chem. Lett. 2010, 20 (5) 1507-1509
47. Decker, M.; Fulton, B. S.; Zhang, B.; Knapp, B. I.; Bidlack, J. M.; Neumeyer, J. L. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands J. Med. Chem. 2009, 52 (23) 7389-7396
48. Mathews, J. L.; Fulton, B. S.; Negus, S. S.; Neumeyer, J. L.; Bidlack, J. M. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties Neurochem. Res. 2008, 33 (10) 2142-2150
49. Antony, J.; Kellershohn, K.; Mohr-Andra, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Trankle, C.; Kostenis, E.; Christopoulos, A.; Holtje, H. D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 2009, 23 (2) 442-450
50. Valant, C.; Sexton, P. M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs Mol. Intervensions 2009, 9 (3) 125-135
51. Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise Br. J. Pharmacol. 2010, 159 (5) 997-1008
52. Steinfeld, T.; Mammen, M.; Smith, J. A.; Wilson, R. D.; Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor Mol. Pharmacol. 2007, 72 (2) 291-302
53. Narlawar, R.; Lane, J. R.; Doddareddy, M.; Lin, J.; Brussee, J.; Ijzerman, A. P. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor J. Med. Chem. 2010, 53 (8) 3028-3037
54. Rodriguez-Martin, I.; de Velasco, E. M.; Rodriguez, R. E. Characterization of cannabinoid-binding sites in zebrafish brain Neurosci. Lett. 2007, 413 (3) 249-254
55. Kosterlitz, H. W.; Lees, G. M.; Wallis, D. I.; Watt, A. J. Non-specific inhibitory effects of morphine-like drugs on transmission in the superior cervical ganglion and guinea-pig isolated ileum Br. J. Pharmacol. 1968, 34 (3) 691P-692P